Scandion Oncology A/S (“Scandion Oncology”) hereby announces that the company has published pre-clinical results with its second drug candidate, SCO-201, for reversal of drug resistance.
ABC transporters are key players in resistance to multiple anti-cancer drugs, leading to cancer treatment failure and cancer-related death. Currently, there are no clinically approved drugs for the reversal of cancer drug resistance caused by ABC transporters. Scandion Oncology has in its pre-clinical study concluded that SCO-201 is a specific, potent, and potentially non-toxic drug candidate for the reversal of ABC transporter mediated resistance in cancer cells.
The results have been published in the international peer reviewed journal Cells as part of the Special Issue “Killing Cancer: Discovery and Selection of New Target Molecules” and is available online: https://www.mdpi.com/2073-4409/9/3/613/pdf
CSO Jan Stenvang comments
“We are very pleased about the results that we have obtained in our pre-clinical studies with SCO-201. These studies conclude that SCO-201 is a highly promising drug candidate for drug-resistant cancer where overexpression of ABC transporters is a key mechanism of drug resistance. This finding is of great importance, in commercial aspects, and for our future development pipeline.”
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com
Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.